Lightnews — Scholar-powered news

Benoît Brilland @benoitbrilland.bsky.social · Sep 9

Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !

ASN Publications @asnpublications.bsky.social · Aug 11

Large-scale kidney transcriptomics identified a 12-gene signature, including CLU and C3, predicting kidney failure in ANCA-associated vasculitis. Read more in #ASNJASN: kidney.pub/JASN0779

@benoitbrilland.bsky.social

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 25

Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social

1

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️

1 1 1

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...

2 1

Benoît Brilland @benoitbrilland.bsky.social · Mar 29

US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! www.nature.com/articles/d41...

75% of US scientists who answered Nature poll consider leaving

More than 1,600 readers answered our poll; many said they were looking for jobs in Europe and Canada.

www.nature.com

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Mar 24

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️

kireports.bsky.social @kireports.bsky.social · Mar 18

Kidney #Transplantation Improves Survival in Antineutrophil Cytoplasmic Antibody–Associated #ANCA #Vasculitides With End-Stage Kidney Disease #ESKD

#VisualAbstract by @DrPSVali

www.kireports.org/ar...

@benoitbrilland.bsky.social

1 2

Benoît Brilland @benoitbrilland.bsky.social · Feb 26

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ek...

1 2

Benoît Brilland @benoitbrilland.bsky.social · Jan 31

Welcome on Bluesky! @brixsilke.bsky.social @odlerb.bsky.social @thkc.bsky.social @paradise-project.bsky.social. I have included you in the « vasculits lovers » starter pack go.bsky.app/HFADD3c

1 5

Benoît Brilland @benoitbrilland.bsky.social · Jan 21

Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️

1 2

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 8

PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 6

Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...

1

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 17

In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/

1 1

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 16

This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

Abstract. The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment (TME) and promotes tumor progression remain unclear. In ...

aacrjournals.org

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 12

First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...

1 4 6

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 10

Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...

Redirecting

doi.org

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 5

Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com

IVW 2026 | 22nd International Vasculitis Workshop

Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...

vasculitis-melbourne2026.com

2 2

Reposted by Benoît Brilland

The Conversation France @france.theconversation.com · Nov 21

Bonjour, bonjour, The Conversation France arrive sur Bluesky ! Ici, pas de breaking news tapageuses ni de buzz éphémères : on mise sur le fond, avec des articles écrits par des chercheurs et chercheuses qui savent de quoi ils parlent, en collaboration avec notre équipe d'excellents journalistes.

22 130 420

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 2

Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)

1 1

Benoît Brilland @benoitbrilland.bsky.social · Dec 3

Hi! Thanks for pinging. I think there is no one-size-fits-all answer. Would consider:
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)

1 4

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Nov 26

Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...

5 5

Reposted by Benoît Brilland

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Nov 24

Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!

Benoît Brilland @benoitbrilland.bsky.social · Nov 20

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!

2 3

Benoît Brilland @benoitbrilland.bsky.social · Nov 21

Vasculitis folks are joining! Welcome in @lynnfussner.bsky.social @matsjunek.bsky.social

Benoît Brilland @benoitbrilland.bsky.social · Nov 20

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!

4

Benoît Brilland @benoitbrilland.bsky.social · Nov 20

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!

3 3

Benoît Brilland @benoitbrilland.bsky.social · Nov 18

My take:
🔹 for detailed emerging therapies, read the #PR3 review
🔸 for detailed pathogenesis, read the #MPO review

1

Benoît Brilland @benoitbrilland.bsky.social · Nov 18

Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3 🔹 and #MPO 🔸
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/

Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis

Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of two major ANCA-associated vasculitis variants a…

bit.ly

1 6 10